|1.||Hayashi, Tetsuya: 2 articles (11/2013 - 05/2005)|
|2.||Matsumura, Yasuo: 2 articles (11/2013 - 05/2005)|
|3.||Brooke, Benjamin S: 2 articles (11/2011 - 10/2010)|
|4.||Kobayashi, Naohiko: 2 articles (09/2008 - 12/2002)|
|5.||Minamino, Tetsuo: 2 articles (08/2004 - 04/2003)|
|6.||Takashima, Seiji: 2 articles (08/2004 - 04/2003)|
|7.||Sanada, Shoji: 2 articles (08/2004 - 04/2003)|
|8.||Kitakaze, Masafumi: 2 articles (08/2004 - 04/2003)|
|9.||Hori, Masatsugu: 2 articles (08/2004 - 04/2003)|
|10.||Asakura, Masanori: 2 articles (08/2004 - 04/2003)|
|1.||Hypertension (High Blood Pressure)
01/01/1986 - "In conclusion, celiprolol proved to be a safe and effective beta-blocker in the treatment of mild and moderate hypertension."
04/01/1989 - "The safety and efficacy of orally administered celiprolol, a new beta 1-selective adrenergic blocking drug with peripheral beta 2-agonist properties, were assessed in 91 patients with mild to moderate systemic hypertension (supine diastolic blood pressure [BP] 95 to 114 mm Hg without medication) using a placebo-controlled, double-blind, randomized, titration-to-effect study design. "
01/01/2003 - "[Efficacy of beta-selective blocker with vasodilatating features celiprolol in patients with mild and moderate hypertension]."
01/01/1991 - "Celiprolol also effectively controlled hypertension in the elderly in the postmarking surveillance study. "
11/01/1988 - "In a 12-month study of 12 patients with essential hypertension treated with once-daily celiprolol, 200 mg, mean supine blood pressure was reduced from 162/102 to 134/84 mm Hg (p less than 0.005)and standing pressures from 155/101 to 134/88 mm Hg (p less than 0.05). "
01/01/1986 - "A multicenter, double-blind placebo controlled study was designed to examine the efficacy of celiprolol in exercise induced angina pectoris. "
10/01/1989 - "The anti-ischemic properties of the new cardioselective beta-adrenoreceptor antagonist celiprolol were investigated in an open study of 12 men (mean age: 58 +/- 6.6 years) with exercise-induced angina pectoris. "
11/01/1988 - "The efficacy and safety of celiprolol in angina pectoris have been demonstrated in multiple studies that highlight its different hemodynamic properties compared with traditional beta-blockers. "
01/01/1986 - "Celiprolol in angina pectoris: a controlled study."
06/01/1985 - "A double blind placebo controlled study of celiprolol in the treatment of angina pectoris."
06/15/2000 - "The absence of a significant efficacy of celiprolol, a beta blocker with vasodilator properties, but exerting stimulation of beta2 receptors, suggests an unfavorable role of this latter property in heart failure. "
03/15/1999 - "A 3-month therapy with celiprolol as an additional therapy to a preexisting heart failure therapy leads to a significant improvement of the ejection fraction in patients with congestive heart failure. "
01/01/1989 - "Third-generation beta-blockers, such as celiprolol, possess both cardioselective and peripheral vasodilatory properties and are therefore potentially beneficial in heart failure."
05/01/2005 - "Also the efficacy of celiprolol, a beta1-selective adrenoceptor antagonist with partial beta2-agonist properties, for heart failure treatment is still controversial. "
03/15/1999 - "In this study, the effect of celiprolol (beta-1-antagonist with beta-2-agonistic activity) on hemodynamic and electrocardiographic parameters of patients with congestive heart failure due to ischemic (iCMP) and non-ischemic (niCMP) origin should be evaluated. "
01/01/1986 - "These results indicate that celiprolol should be effective in controlling the exercise-induced increase in heart rate in patients with chronic atrial fibrillation. "
08/01/1987 - "Accordingly, a randomized, double-blind, cross-over placebo-controlled study was performed to assess the efficacy of celiprolol, a new cardioselective beta-blocker with partial intrinsic sympathomimetic activity, on exercise performance in nine men with chronic atrial fibrillation. "
11/01/1988 - "In a clinical study celiprolol has bee found to decrease ventricular rate in patients with chronic atrial fibrillation. "
01/01/1986 - "Effect of orally administered celiprolol in patients with chronic atrial fibrillation."
01/01/1986 - "The influence of oral celiprolol on exercise induced tachycardia was evaluated in 23 patients with chronic stable atrial fibrillation in a dose-titration study. "
|5.||Coronary Disease (Coronary Heart Disease)
06/30/1987 - "In the present study, the beta-receptor-blocker Celiprolol was tested for its antianginal effects during an observation period of 12 months; 29 patients, both male and female, with definite coronary heart diseases, were subjected to this study. "
06/30/1987 - "[Treatment of coronary heart disease with the beta-1-receptor blocker celiprolol in a long-term study over a 12-month period]."
06/30/1987 - "The indication for the use of Celiprolol in long-term treatment of coronary heart disease was impressingly confirmed."
04/01/1987 - "[Hemodynamic effects of intravenously administered celiprolol in patient with coronary heart disease and depressed left ventricular function]."
06/01/1985 - "The cardiovascular effects of celiprolol in healthy volunteers and patients with coronary heart disease."
|7.||Collagen Type I (Type I Collagen)
|8.||Messenger RNA (mRNA)